Psychedelic Business Spotlight – June 10
This week in psychedelic business news: Cybin acquires a Phase 1 DMT trial from Entheon; Numinus completed the acquisition of Novamind, MindMed’s stock is removed from an index; and more!
novamind
Psychedelic Business Spotlight – April 15
This week in psychedelic business news: The industry’s first major merger; NeonMind launches clinics; a portfolio of patents is acquired.
Numinus Acquiring Novamind in First Major Psychedelics Merger
This deal will make Numinus the psychedelic medicines company with the highest revenue, though of course there is still a long road to profitability.
Psychedelic Business Spotlight: November 19
This week in psychedelic business news: Companies partner on new dosage method; MindMed investigates LSD microdosing; Health Canada allows a psilocybin production campus.
Psychedelic Business Spotlight: October 8, 2021
This week in psychedelic business news: Enveric Biosciences uses AI to identify viable psychedelic drug candidates; Novamind launches end-of-life palliative care program; and PharmaTher tests ketamine to treat Parkinson’s Disease.
Psychedelic Business Spotlight: September 17, 2021
This week in psychedelic business news: Wesana teams up with MAPS, MindBio Therapeutics announces world-class research and drug development facility, and Awakn Life Sciences buys up ketamine clinics across the Nordics.
Psychedelic Business Spotlight: July 30, 2021
This week in psychedelic business news: More psychedelic-assisted therapy clinics, recruitment begins in early DMT trial, and Filament gets more Health Canada love.
End of content
End of content